文献速递瓣膜外科主动脉外科

主动脉瓣修复治疗主动脉瓣关闭不全或扩张:技术演进与远期结局

Aortic Valve Repair for Aortic Insufficiency or Dilatation: Technical Evolution and Long-term Outcomes.
PubMed 文献 · Ann Thorac Surg · 2020-05-08

该研究回顾1996至2017年560例因主动脉瓣关闭不全接受主动脉瓣修复(AVR)的患者,其中三叶瓣415例、二叶瓣145例,David手术313例、单纯瓣叶修复247例。结论认为中期随访中AVR持久且瓣膜相关并发症率和死亡率低。

要点

  • 10年免于再手术率为88%,再手术主要因复发性关闭不全。
  • 所有瓣膜相关并发症累积线性发生率为每患者年2%。

核心结论

  • 主动脉瓣修复治疗关闭不全在中期随访中持久,瓣膜相关并发症率和死亡率低。

研究设计与样本

  • 回顾性队列研究,纳入1996至2017年560例连续接受主动脉瓣修复的患者,平均年龄57±16岁,三叶瓣415例(74%)、二叶瓣145例(26%),David手术313例(56%)、单纯瓣叶修复247例(44%),临床与超声随访完整率97%,平均随访6.3±4.6年。

主要发现

  • 39例因复发性关闭不全再手术,其中单纯关闭不全25例、合并瓣膜狭窄5例,心内膜炎导致再手术9例(每患者年0.2%),10年免于再手术率88%。
  • 所有瓣膜相关并发症累积线性发生率为每患者年2%。

临床怎么用

  • 对于主动脉瓣关闭不全患者,AVR可作为瓣膜置换的替代选择,中期耐久性良好且瓣膜相关并发症风险低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Aortic valve repair (AVR) is an attractive alternative to valve replacement for the treatment of aortic valve insufficiency. Here we report on the midterm outcomes after AVR for aortic valve insufficiency with an emphasis on durability of repair. METHODS: Between 1996 and 2017, 560 consecutive patients (mean age, 57 ± 16 years) underwent various AVR procedures on tricuspid (n = 415, 74%) and bicuspid (n = 145, 26%) aortic valves. In 313 patients (56%) the David procedure was performed, whereas in 247 patients (44%) cusp repair without aortic root procedure was conducted. Concomitant procedures were coronary artery bypass grafting in 82 patients (15%) and mitral valve repair in 47 patients (8%). Clinical and echocardiographic follow-up was complete in 97% of patients. Mean follow-up was 6.3 ± 4.6 years. RESULTS: Thirty-day mortality was 1.4% (n = 8). Late mortality was observed in 132 patients with cardiovascular events accounting for mortality in 13 patients: Survival at 10 years was 70%. Reoperation on the aortic valve was performed on 39 patients for recurrent insufficiency, isolated in 25, or combined with valve stenosis in 5 patients; endocarditis accounted for reoperation in 9 patients (0.2% per patient-year). Freedom from reoperation was 88% at 10 years. Cumulative linearized incidence of all valve-related complications was 2% per patient per year. CONCLUSIONS: AVR for insufficiency is a durable procedure with low valve-related morbidity and mortality in the midterm.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Salem R, Zierer A, Karimian-Tabrizi A, et al. Aortic Valve Repair for Aortic Insufficiency or Dilatation: Technical Evolution and Long-term Outcomes. Ann Thorac Surg. 2020. PMID: 32437674. doi:10.1016/j.athoracsur.2020.03.105

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。